[Jeff Christiansen]

So 2022 deal-flow in this industry has been very quiet in H1, but there is a lot of cash on balance sheets (estimated $500b by year end) able to be deployed. Does anyone who works in this space see much going on?

[Jamie M]

Things have changed in Biotech/Pharma space since 2022. We have seen a spike in acquisitions in the area likely due to patent drop off, a bit more stability in the political arena, uptick in venture fund investments and desire to not be left behind on technologies such as AI, gene editing or the race to treat the large population suffering from obesity.

[Steve]

I agree with Jamie, the Biotech/Pharma space has seen a significant rise in M&A activity. Loss of Exclusivity for commercial products drives Pharma companies to rebuild pipelines to fuel future revenue loss.

[Author]

Posts